16-Sep-2024 11:00 PM CST : Amgen Inc., a leader in biotechnology-based human therapeutics, has been gaining attention from investors and analysts alike due to its solid financials and promising clinical updates. According to recent reports, Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating today.
The company's pipeline is also showing promise, with several treatments in various stages of development. For instance, Amgen's eye disease treatment, veligrotug, has shown promising results and could potentially rival the company's $28 billion acquisition. This news has sent Viridian Therapeutics stock jumping on Tuesday.
Despite this positive outlook, not all analysts are convinced that AMGN is a buy. Wells Fargo analyst Mohit Bansal assigned a Hold rating to Amgen (AMGN - Research Report) on September 6 and set a price target of $325.00. Barclays analyst Carter Gould has also maintained their neutral stance on AMGN stock, giving a Hold rating.
However, the majority of analysts seem to be optimistic about Amgen's prospects. Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN), and Zacks.com users have recently been watching Amgen quite a bit due to its solid uptrend and Strong Buy rating from Nasdaq.
* AI generated summary of articles
AMGN News
16-Sep-2024 5:00 PM CST - Zacks Amgen (AMGN) Rises Higher Than Market: Key Facts Amgen (AMGN) ended the recent trading session at $335.26, demonstrating a +0.85% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.13%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.52%.
10-Sep-2024 4:50 PM CST - YAHOO!Finance Why Amgen (AMGN) Outpaced the Stock Market Today Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
9-Sep-2024 12:47 AM CST - Business Insider Wells Fargo Issues a Hold Rating on Amgen (AMGN) Wells Fargo analyst Mohit Bansal assigned a Hold rating to Amgen (AMGN - Research Report) on September 6 and set a price target of
8-Sep-2024 5:20 AM CST - MSN Amgen Inc. (AMGN): Why Do Hedge Funds Recommend This Biotech Stock? According to stock analysis, there are 665 stocks in the biotechnology ... beating its benchmark by 150 percentage points. (see more details here) Amgen Inc. (NASDAQ:AMGN) is an innovator in human therapies based on biotechnology. The immune system ...
3-Sep-2024 9:02 AM CST - YAHOO!Finance Amgen Insiders Sell US$4.0m Of Stock, Possibly Signalling Caution Amgen insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Latest AMGN Trades by Congress Members
7-AUG-2024 - C. Scott Franklin, FL (District 18) purchased between $50,001 and $100,000.
16-Sep-2024 11:00 PM CST : Amgen Inc., a leader in biotechnology-based human therapeutics, has been gaining attention from investors and analysts alike due to its solid financials and promising clinical updates. According to recent reports, Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating today.
The company's pipeline is also showing promise, with several treatments in various stages of development. For instance, Amgen's eye disease treatment, veligrotug, has shown promising results and could potentially rival the company's $28 billion acquisition. This news has sent Viridian Therapeutics stock jumping on Tuesday.
Despite this positive outlook, not all analysts are convinced that AMGN is a buy. Wells Fargo analyst Mohit Bansal assigned a Hold rating to Amgen (AMGN - Research Report) on September 6 and set a price target of $325.00. Barclays analyst Carter Gould has also maintained their neutral stance on AMGN stock, giving a Hold rating.
However, the majority of analysts seem to be optimistic about Amgen's prospects. Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN), and Zacks.com users have recently been watching Amgen quite a bit due to its solid uptrend and Strong Buy rating from Nasdaq.
* AI generated summary of articles
AMGN News
16-Sep-2024 5:00 PM CST - Zacks Amgen (AMGN) Rises Higher Than Market: Key Facts Amgen (AMGN) ended the recent trading session at $335.26, demonstrating a +0.85% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.13%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.52%.
10-Sep-2024 4:50 PM CST - YAHOO!Finance Why Amgen (AMGN) Outpaced the Stock Market Today Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
9-Sep-2024 12:47 AM CST - Business Insider Wells Fargo Issues a Hold Rating on Amgen (AMGN) Wells Fargo analyst Mohit Bansal assigned a Hold rating to Amgen (AMGN - Research Report) on September 6 and set a price target of
8-Sep-2024 5:20 AM CST - MSN Amgen Inc. (AMGN): Why Do Hedge Funds Recommend This Biotech Stock? According to stock analysis, there are 665 stocks in the biotechnology ... beating its benchmark by 150 percentage points. (see more details here) Amgen Inc. (NASDAQ:AMGN) is an innovator in human therapies based on biotechnology. The immune system ...
3-Sep-2024 9:02 AM CST - YAHOO!Finance Amgen Insiders Sell US$4.0m Of Stock, Possibly Signalling Caution Amgen insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
